Skip to nav Skip to content

Every three minutes, an American is diagnosed with leukemia, lymphoma or myeloma. It is an alarming statistic, but top hematologists from across the world are coming together to discuss the latest research and treatment advances to help those blood cancer patients have better outcomes. This week, more than 30,000 physicians and scientists gathered in New Orleans for the 64th Annual American Society of Hematology (ASH) Annual Meeting and Exposition

Moffitt Cancer Center was well represented at the conference, presenting more than 55 abstracts on the latest research in the treatment of blood malignancies. Topics include identifying factors that can help predict patient outcomes to CAR T-cell therapy, how monoclonal antibody therapy for COVID can improve outcomes for stem cell transplant patients, and whether racial and ethnic differences impact outcomes in multiple myeloma. You can learn more about Moffitt’s presentations at the ASH annual meeting by visiting and by reading the stories below.


Read Moffitt’s ASH 2022 Stories 

Moffitt Investigates First-of-Its-Kind Cellular Therapy in MDS Patients

Novel approach uses mismatched donor lymphocytes to activate patient’s immune system

Donor CAR T May Increase Remission in Relapsed or Refractory AML Patients

Good clinical responses seen for using genetically modified product

New Therapy Shows Promise for Myelodysplastic Syndrome Patients

SX-682 works by targeting both adverse immune cells and cancer cells

Study Highlights Potential Disparities for CAR T Patients with Multiple Myeloma

Hispanics had lower response rates